24.4 C
New York
Friday, June 12, 2026

Tag: fatigue

newssourceFORcompanyinformationcontent1marketreleases

Infinix HOT 60 Pro+ Officially Launches, Setting a New Global Record for the World’s Slimmest 3D-Curved Screen Phone

HONG KONG, July 25, 2025 /PRNewswire/ -- Infinix today unveiled its latest HOT 60 Series lineup, including the HOT 60 Pro+, HOT 60 Pro, HOT...

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...

Happy Docs Make Happy Patients

AI technology boosts face-to-face time with patients, earns Mercy national recognition for physician satisfaction ST. LOUIS, July 23, 2025 /PRNewswire/ -- Mercy's strategic and carefully planned...

PhysFlex Launches Summer Compression Wear Collection for Travel, Workouts, and Active Lifestyles

Breathable joint support solutions address swelling, fatigue, and pain relief for travelers, athletes, and frontline workers this season 
Breathable joint support solutions address swelling, fatigue, and pain relief for travelers, athletes, and frontline workers this season

Muscle Building Supplements 2025: CrazyBulk Introduces Effective Bodybuilding Supplements For Muscle Growth, Bulking, Cutting And Strength in USA

Muscle Building Supplements: A Game-Changer in Strength Training Programs 
Muscle Building Supplements: A Game-Changer in Strength Training Programs

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

Ready or Not: Most HR Leaders Say They’re Prepared for Change–Are Their Organizations?

NEW YORK, July 22, 2025 /PRNewswire/ -- From rapid advances in AI to geopolitical volatility and evolving workforce expectations, organizations are facing historic levels...

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

Industrial Floor Mats Market Size to Grow USD 3987.1 Million by 2030 at a CAGR of 2.3% | Valuates Reports

BANGALORE, India, July 21, 2025 /PRNewswire/ -- Industrial Floor Mats Market is Segmented by Type (Anti-fatigue Mats, Anti-static Mats, Traction Mats, Non-conductive Mats), by...

Natural Appetite Suppressant: Why More Are Choosing PhenQ Over Weight Loss Injections for Safer Weight Management Results in 2025

New York City, NY, July 21, 2025 (GLOBE NEWSWIRE) -- PhenQ is leading the 2025 weight loss revolution with a science-backed natural appetite suppressant—no needles, no harsh side effects, just sustainable, healthy weight control

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFatigue

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers